BRIEF-Merck & Co Inc Says FDA Sets PDUFA Date Of June 19, 2026 For Welireg And Keytruda

Reuters02-28
BRIEF-Merck & Co Inc Says FDA Sets PDUFA Date Of June 19, 2026 For Welireg And Keytruda

Feb 28 (Reuters) - Merck & Co Inc MRK.N:

  • KEYTRUDA® (PEMBROLIZUMAB) PLUS WELIREG® (BELZUTIFAN) GIVEN AS ADJUVANT THERAPY REDUCED THE RISK OF DISEASE RECURRENCE OR DEATH BY 28% COMPARED TO KEYTRUDA MONOTHERAPY IN CERTAIN PATIENTS WITH EARLIER-STAGE RENAL CELL CARCINOMA $(RCC)$

  • MERCK & CO INC - KEYTRUDA PLUS WELIREG REDUCES RISK OF RECURRENCE OR DEATH BY 28%

  • MERCK & CO INC - FDA ACCEPTS PRIORITY REVIEW FOR WELIREG AND KEYTRUDA COMBINATION

  • MERCK & CO INC - FDA SETS PDUFA DATE OF JUNE 19, 2026 FOR WELIREG AND KEYTRUDA

Source text: ID:nBw7Rg3KLa

Further company coverage: MRK.N

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment